Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

ClinicalTrials.gov ID: NCT02301624

Public ClinicalTrials.gov record NCT02301624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)

Study identification

NCT ID: NCT02301624
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 117 participants

Conditions and interventions

Conditions

Refractory Generalized Myasthenia Gravis

Interventions

Eculizumab Biological
Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 11, 2014
Primary completion: Jan 14, 2019
Completion: Jan 14, 2019
Last update posted: Feb 4, 2020

2014 – 2019

United States locations

U.S. sites: 26
U.S. states: 17
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35233	—
Not listed	Los Angeles	California	90033	—
Not listed	Orange	California	92868	—
Not listed	Palo Alto	California	94304	—
Not listed	San Francisco	California	94115	—
Not listed	New Haven	Connecticut	06519	—
Not listed	Jacksonville	Florida	32209	—
Not listed	Miami	Florida	33136	—
Not listed	Tampa	Florida	33612	—
Not listed	Springfield	Illinois	62702	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Baltimore	Maryland	21201-1595	—
Not listed	Baltimore	Maryland	21287-0876	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Burlington	Massachusetts	01805	—
Not listed	Las Vegas	Nevada	89145	—
Not listed	Chapel Hill	North Carolina	27599	—
Not listed	Charlotte	North Carolina	28207	—
Not listed	Durham	North Carolina	27710	—
Not listed	Columbus	Ohio	43210	—
Not listed	Portland	Oregon	97239	—
Not listed	San Antonio	Texas	78229	—
Not listed	Burlington	Vermont	05401	—
Not listed	Seattle	Washington	98195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02301624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 4, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02301624 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →